Raelipskie Partnership’s X4 Pharmaceuticals XFOR Stock Holding History

Raelipskie Partnership’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-33	Closed	-$236	–	125
2025 Q1	$236	Hold	33	–	–	﹤0.01%	118
2024 Q4	$734	Hold	33	–	–	﹤0.01%	115
2024 Q3	$669	Hold	33	–	–	﹤0.01%	120
2024 Q2	$580	Hold	33	–	–	﹤0.01%	95
2024 Q1	$1.39K	Hold	33	–	–	﹤0.01%	94
2023 Q4	$839	Buy	+33	New	+$802	﹤0.01%	90

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raelipskie Partnership's XFOR Position: Q2 2025 in Review

Raelipskie Partnership sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 33 shares — an estimated $236 sold.

Raelipskie Partnership first reported a position in XFOR in Q4 2023 and held it in 6 quarters. The position peaked at $1.39K in Q1 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

Raelipskie Partnership reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Raelipskie Partnership sold 33 X4 Pharmaceuticals shares in Q2 2025, an estimated $236.
Raelipskie Partnership first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Raelipskie Partnership's X4 Pharmaceuticals position peaked at $1.39K in Q1 2024.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Raelipskie Partnership's 13F filing for Q2 2025, filed 6 Aug 2025.